Home / Clinical Laboratory / Clinical Analyzer Calibrators and Reagents / Reagents / Reagent / Reagent Immulite® 2000 Cancer BR-MA (CA15-3) For Immulite® 2000 System 200 Tests10380983
Picture of Reagent Immulite® 2000 Cancer BR-MA (CA15-3) For Immulite® 2000 System 200 Tests10380983

Reagent Immulite® 2000 Cancer BR-MA (CA15-3) For Immulite® 2000 System 200 Tests10380983

Reagent-Immulite®-2000-Cancer-BR-MA-(CA15-3)-For-Immulite®-2000-System-200-Tests10380983

SKU #

#925116

MPN #

10380983

Brand

Siemens

Stock

In Stock

Quantity

100

Features

BR-MA CA 15-3 RGT 200/BX IMMULITE 2000

$393.35 USD

Product Specifications Product Usage Additional Information
Print
Attribute Name Attribute Value
McKesson # 925116
Manufacturer # 10380983
Brand IMMULITE® 2000
Manufacturer Siemens
Application Reagent
Container Type Wedge
For Use With For Immulite® 2000 System
Form Liquid
Number of Tests 200 Tests
Sample Type Serum Sample
Storage Requirements Requires Refrigeration
Test Name BR-MA (CA15-3)
Test Type Cancer
Type Two-step Sequential Chemiluminescent Immunometric Assay
UNSPSC Code 41116010
Compare Selected Items Email

Similar Items

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

  • For the quantitative measurement of CA15-3 antigen in human serum, as an aid in the detection of recurrence in previously treated stage II and stage III breast cancer patients, and in the management of metastatic breast cancer patients by monitoring disease progression or response to treatment
  • Incubation Cycles: 2 × 30 minutes